Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DTIL

Precision BioSciences, Inc.

Healthcare | Biotechnology
$6.96 as of 2026-09-05 03:41 UTC
Market Cap$170M
Volume47.9K
EPS (TTM)$-3.56

Precision BioSciences, Inc. (NASDAQ: DTIL) is a $170M biotechnology company trading at $6.96. Figures from SEC EDGAR and market feeds; updated 2026-09-05 03:41 UTC.

What Precision BioSciences, Inc. does

The company is a clinical-stage gene editing firm developing therapies using its proprietary ARCUS platform technology. ARCUS works by cutting DNA at specific locations to make insertions, eliminations, or excisions, and differs from competing technologies through its unique cutting mechanism, smaller size, and simpler single-component structure that requires no guide RNA. The company is advancing two clinical-stage in vivo gene editing programs, including PBGENE-HBV, which targets chronic hepatitis B by eliminating the viral DNA that persists in liver cells and currently has no cure.

Summarized from Precision BioSciences, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Quote
Price$6.96
Market cap$170M
Volume47.9K shares
Valuation
EPS (TTM)$-3.56
Price/book1.84×

Revenue, margins & earnings

FY2021: net loss $31M on revenue $116M$116MFY2021FY2022: net loss $112M on revenue $25M$25MFY2022FY2023: net loss $61M on revenue $49M$49MFY2023FY2024 Revenue: $69M — margin split not shown (non-operating gains)$69MFY2024FY2025: net loss $46M on revenue $34M$34MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-05
Most recent filed transactions — June 2026:
  • 2026-06-05Brown MelindaA20,979—
  • 2026-06-05Frankel StanleyA20,979—
  • 2026-06-05Germano Geno JA20,979—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Precision BioSciences, Inc. do?

The company is a clinical-stage gene editing firm developing therapies using its proprietary ARCUS platform technology.

What is DTIL's valuation?

DTIL trades at $6.96, as of 2026-09-05.

When did DTIL last file with the SEC?

Precision BioSciences, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-09-05 03:41 UTC. This page is also available as JSON at /api/data?ticker=DTIL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DTIL and 5,000+ tickers.

Create a free account — keep DTIL
For your agent
GET /api/data?ticker=DTIL

This page as JSON via rel="alternate" · REST API docs · MCP server (59 tools) · llms.txt